Friday, December 4, 2020
Mastering the Treatment of Myeloid Malignancies in the era of Personalized Medicine
The complementary enduring program provides an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with myeloid malignancies including aplastic anemia, paroxysmal nocturnal hemoglobinuria, MDS, AML, MPN and related myeloid malignancies. This program brought together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.
Preparing for Personalized Care in MDS
Integrating Innovative Treatments a Cohesive Potent Care Model
This CE activity has been developed in collaboration with the Aplastic Anemia and MDS International Foundation, and was presented at the Friday Satellite Symposium preceding the 62nd ASH Annual Meeting and Exposition on December 4, 2020.
Emerging Therapies and Management Strategies for MDS and Myeloid Malignancies
The symposium, recorded for the virtual ONS Bridge platform on September, 17th 2020, is targeted to clinical nursing professionals in oncology. Case studies will be used to illustrate treatment decision-making and therapeutic challenges.
- Latest developments in diagnosing and treating myeloid malignancies;
- Emerging treatment options for low-risk MDS, high-risk MDS, AML, and MDS/MPN overlap;
- Disease management for chronic anemia, side effects and treatment adherence;
- Psychosocial considerations and palliative care to improve the quality of life for this patient population.
- Christina Cline, RN, BSN, CCRC, Senior Registered Nurse Manager,
University of Florida, Gainesville, FL
- Allyson Price, MPAS, PA-C, Physician Assistant, Department of Leukemia,
University of Texas MD Anderson Cancer Center, Houston, TX
- Kirsten Roblee, RN, BSN, OCN, Assistant Nurse Manager,
The James Cancer Hospital and Solove Research Institute, Columbus, OH
Method of Participation
There are no fees for participating in and receiving credit for this activity. Participants must:
- Read the learning outcomes and faculty disclosures
- Watch and study the educational activity
- Successfully complete the Nursing CE Assessment with a score of 70% or better
- Complete the evaluation form
Once you’ve completed the appropriate steps and scored a 70% or greater, you will be able to download/print your certificate
Estimated time to complete activity: 1.5 hours
Date of initial release: November 9, 2020
Valid for CE credit through: November 8, 2021
Seventh International Bone Marrow Failure Scientific Symposium
*All content now available On Demand*
Symposium Information and Registration
An Intensive Three-Day Virtual Conference Convening International Experts at the Forefront of Research and Treatment of Bone Marrow Failure Disease. This symposium brought together physicians treating these diseases and laboratory researchers studying the immunology and cell biology of bone marrow failure disease to:
- Discuss current areas of controversy
- Share recent research results
- Propose specific recommendations for the highest priority directions for basic and clinical research needed to advance the field of research
Once thought of as distinct, aplastic anemia, myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) are now believed to be linked by similar pathophysiologic pathways.
With exciting new developments in the treatment of these diseases and new insights into the molecular pathogenesis of the diseases, AAMDSIF is coordinating this symposium to explore opportunities for collaborative research.
The symposium program has been designed to address the most up-to-date issues in each topic area and to encourage participant interaction. Each session includes presentations by experts in the field followed by open discussion.
For more information, please contact AAMDSIF Senior Director of Health Professional Programs Alice Houk at email@example.com
Virtual Tumor Board: Diagnosis Management of Myelodysplastic Syndromes
Dates Available: May 26, 2020 to May 25, 2021
David P. Steensma, MD, FACP
Reza Nejati, MD
Ilene Galinsky, BSN, MSN, ANP-C
The Clinical Management of Myeloid Malignancy: The Coming Age of Targeted Therapies
Friday, December 6, 2019 | 12:00-4:00 pm
Orange County Convention Center
This Satellite Symposium, which preceded the 61st ASH Annual meeting, was organized by the Cleveland Clinic Taussig Cancer Institute Leukemia Program and the Aplastic Anemia and MDS International Foundation.
The complimentary enduring program provides an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The program brought together leaders in disease research and clinical practice to explore solutions on improving the care of patients.
Myelodysplastic Syndromes Transitioning to Acute Myeloid Leukemia
Thursday, January 23, 2020 | 1:00 pm ET
At the conclusion of this program, participants will be able to:
- Describe a management strategy for high-risk MDS/AML based on the clinical presentation, diagnostic workup and recent research findings
- Explain the role of genetic testing in risk assessment and stratification for this patient population
- Identify emerging treatment options for high-risk MDS and secondary AML
- Discuss the roles of a multidisciplinary health care team in addressing treatment goals and providing patient education to improve outcomes, including guiding patients and caregivers in decision making, financial issues, and palliative care options
- Identify resources for support and education for patients
BMT and Immunotherapies for Pediatric Leukemia: Current and Novel Treatments and Financial Implications
Sponsored jointly by the National Marrow Donor Program® / Be The Match® and the Aplastic Anemia and MDS International Foundation.
In this recorded webinar, you'll learn that bone marrow transplant (BMT) and immunotherapies continue to quickly evolve for pediatric leukemia, varying in the pathophysiology and management. For health professionals, knowledge of these treatment options and potential toxicities is necessary to manage and provide patients with safe and effective evidence-based care. When choosing these treatment options, families can face additional financial decisions and need assistance to manage the financial implications.
- Vicki Szenes, MS, RN, CPNP, CPHON®, Pediatric Nurse Practitioner ,
Memorial Sloan-Kettering Cancer Center
- Meghan Wellenbrink, BSN, RN, CPHON, CAR-T Cell Clinical Nurse Coordinator,
Memorial Sloan-Kettering Cancer Center